Skip to main content

Advertisement

SpringerLink
Log in

153Sm-EDTMP for bone pain palliation in skeletal metastases

  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

153Sm-ethylene diamine tetramethylene phosphonate (EDTMP) is a widely available and extensively tested radiopharmaceutical for systemic radionuclide therapy in patients with symptomatic multiple skeletal metastases. Its use is approved for any secondary bone lesion which has been shown to accumulate 99mTc-methylene diphosphonate, including breast carcinoma. The molecule is stable in vitro and upon injection more than 50% of the dose is avidly fixed by lesional and non-lesional bone, with the rest being rapidly eliminated unchanged via the urine. The short half-life (46.3 h), the relatively low-energy beta emissions (E ave=233 keV) and the gamma emission (103 keV) make 153Sm a very attractive radionuclide, allowing therapeutic delivery of short-range electrons at relatively high dose rates with external imaging to corroborate biodistribution and possible dosimetric estimates. For a standard dose of 2,590 MBq/70 kg, the estimated radiation dose to metastases is 86.5 Gy. Critical organs are the bladder wall (2.5 Gy/2,590 MBq) and red marrow (4 Gy/2,590 MBq), with the latter being the critical factor in clinical practice as the dose-limiting factor is marrow radiotoxicity. The therapy has, however, proved safe provided that the platelet count exceeds 100×109/l and the white blood cell count exceeds 3.5×109/l. Clinical data obtained in fewer than 250 patients, within several studies, lead to the following conclusions: a dose of 37 MBq/kg has a better therapeutic ratio than a dose of 18.5 MBq/kg; the mean pain palliation rate after a single treatment in breast cancer is about 80%; toxicity is generally mild and transitory; and re-treatments are effective and safe provided that haematological values have fully recovered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A, B

Similar content being viewed by others

References

  1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987; 55:61–66.

    CAS  PubMed  Google Scholar 

  2. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991; 18:11–15.

    CAS  Google Scholar 

  3. Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003; 97 (Suppl):834–839.

    Google Scholar 

  4. Lipton A. Bisphosphonates and breast carcinoma: present and future. Cancer 2000; 88 (Suppl):3033–3037.

    Google Scholar 

  5. Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 2003; 29:321–327.

    Article  CAS  PubMed  Google Scholar 

  6. Hoskin PJ. Radiotherapy for bone pain. Pain 1995; 63:137–139.

    Article  CAS  PubMed  Google Scholar 

  7. Dearnaley DP, Bayly RJ, A’Hern RP, Gadd J, Zivanovic MM, Lewington VJ. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol 1992; 4:101–107.

    CAS  Google Scholar 

  8. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 1994; 30:1187–1194.

    CAS  PubMed  Google Scholar 

  9. McEwan AJ. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997; 27:165–182.

    CAS  PubMed  Google Scholar 

  10. Serafini AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42:895–906.

    CAS  PubMed  Google Scholar 

  11. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 2000; 88 (Suppl):2934–2939.

    Google Scholar 

  12. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastases. Q J Nucl Med 2001; 45:91–99.

    CAS  PubMed  Google Scholar 

  13. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28:495–504.

    PubMed  Google Scholar 

  14. Turner JH, Claringbold PG, Hetherington EL, Sorby P, Martindale AA. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. J Clin Oncol 1989; 7:1926–1931.

    CAS  PubMed  Google Scholar 

  15. Podoloff DA, Kasi LP, Kim EE, Fossella FV, Bhadkamar VA. Evaluation of Sm-153-EDTMP as a bone imaging agent during a therapeutical trial. J Nucl Med 1991; 32:A918.

    Google Scholar 

  16. Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, Hartnett S, Ferency S, Addison SJ, Appelbaum F, Gordon EE. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 1993; 34:1031–1036.

    CAS  PubMed  Google Scholar 

  17. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose of samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991; 27:1084–1086.

    Article  CAS  PubMed  Google Scholar 

  18. Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, Stringham LM, Ketring AR. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med 1989; 30:1814–1818.

    CAS  PubMed  Google Scholar 

  19. Bayouth JE, Macey DJ, Kasi LP, Fossella FV. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 1994; 35:63–69.

    CAS  PubMed  Google Scholar 

  20. Heggie JC. Radiation absorbed dose calculations for samarium-153-EDTMP localized in bone. J Nucl Med 1991; 32:840–844.

    CAS  PubMed  Google Scholar 

  21. Logan KW, Volkert WA, Holmes RA. Radiation dose calculations in persons receiving injection of samarium-153-EDTMP. J Nucl Med 1987; 28:505–509.

    CAS  PubMed  Google Scholar 

  22. Wu H, Tan T, Fang L, Zhang X. Evaluation of efficacy of153Sm-EDTMP in patients with painful bone metastases of breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:716–718.

    CAS  PubMed  Google Scholar 

  23. Farhanghi M, Homes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33:1451–1458.

    CAS  PubMed  Google Scholar 

  24. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34:1839–1844.

    CAS  PubMed  Google Scholar 

  25. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15:784–795.

    CAS  PubMed  Google Scholar 

  26. Alberts AS, Smit BJ, Louw WKA, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol 1997; 43:175–179.

    Article  CAS  PubMed  Google Scholar 

  27. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jacobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, Larikka M, Nikula T, Romppainen ML, Vanaselja T, Vuorimaki O. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38 (Suppl I):123–127.

    Google Scholar 

  28. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol 1993; 20 (Suppl 2):22–26.

    Google Scholar 

  29. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D. A dose-controlled study of 153-Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33:1583–1591.

    Article  CAS  PubMed  Google Scholar 

  30. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574–1581.

    CAS  PubMed  Google Scholar 

  31. Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan L, He YJ. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med 1999; 26:2–7.

    Article  CAS  PubMed  Google Scholar 

  32. Donaldson G. A new approach to calculating pain measurements for cancer patients. Sci Comput Automation 1992; January:45–48.

    Google Scholar 

  33. Li L, Liang Z, Deng H, Kuang A, Tan T, Luo S. Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J 2002; 115:1096–1098.

    CAS  PubMed  Google Scholar 

  34. Dolezal J, Vizd’a J, Cermakova E. Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP. Vnitr Lek 2003; 49:189–193.

    CAS  PubMed  Google Scholar 

  35. Maini CL, Sciuto R, Romano L, Bergomi S. Radionuclide therapy with bone seeking radionuclides in palliation of painful bone metastases. J Exp Clin Cancer Res 2003; 22:71–74.

    Google Scholar 

  36. Sciuto R, Tofani A, Festa A, Giannarelli D, Pasqualoni R, Maini CL. Short- and long-term effects of186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 2000; 41:647–654.

    CAS  PubMed  Google Scholar 

  37. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 2001; 66:101–109.

    Article  CAS  PubMed  Google Scholar 

  38. Samaratunga RC, Thomas SR, Hinnefeld JD, von Kuster LC, Hyams DM, Moulton JS, Matthew I, Sperling MI, Maxon HR III. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from Rhenium-186(Sn)-HEDP. J Nucl Med 1995; 36:336–350.

    CAS  PubMed  Google Scholar 

  39. Mauch PM. Treatment of metastatic cancer to bone. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. Philadelphia: Lippincott; 1993:1564–1579.

  40. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG, Broccatelli M. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 1996; 17:799–804.

    CAS  PubMed  Google Scholar 

  41. Sciuto R, Festa A, Tofani A, Pasqualoni R, Semprebene A, Cucchi R, Ferraironi A, Rea S, Maini CL. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy. Clin Ter 1998; 149:43–47.

    CAS  PubMed  Google Scholar 

  42. Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL. Effects of low-dose cisplatin on89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43:79–86.

    CAS  PubMed  Google Scholar 

  43. Turner JH, Claringold PG, Martindale AA. Samarium-153-EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastases. Eur J Nucl Med 1992; 16:s125.

    Google Scholar 

  44. McCready VR, O’Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med 2002; 29:1271–1275.

    CAS  Google Scholar 

  45. Wallenstein SL. Measurement of pain and analgesia in cancer patients. Cancer 1984; 53:2260–2266.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank S. Rea, M.D., R. Pasqualoni, M.D., and A. Festa, M.D., for assistance with data collection.

Author information

Author notes

  1. Carlo L. Maini

    Present address: , Via Fontana L’Abate 11, 03010, Patrica (FR), Italy

Authors and Affiliations

  1. Nuclear Medicine Department, “Regina Elena” National Cancer Institute, Rome, Italy

    Carlo L. Maini, Serenella Bergomi, Luisa Romano & Rosa Sciuto

Authors
  1. Carlo L. Maini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serenella Bergomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Luisa Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rosa Sciuto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo L. Maini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maini, C.L., Bergomi, S., Romano, L. et al. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 31 (Suppl 1), S171–S178 (2004). https://doi.org/10.1007/s00259-004-1540-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1540-y

Keywords

Search

Navigation